XBIO Xenetic Biosciences Inc.

1
+0.06  (+6%)
Previous Close 0.94
Open 0.95
Price To Book 0.36
Market Cap 6,284,915
Shares 6,284,915
Volume 2,252,046
Short Ratio
Av. Daily Volume 245,675
Stock charts supplied by TradingView

NewsSee all news

  1. Xenetic Biosciences, Inc. Announces Research and Development Collaboration with Scripps Research to Advance XCART(TM) Platform

    - Represents significant milestone in strategic development plan to advance XCART through academic collaborations - - Provides access to leading research institution with world renowned immunology expertise - - Company

  2. Xenetic Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update

    - Company poised to execute on near- and long-term value-driving milestones to advance preclinical development of its XCART™ CAR T therapy platform -- Continuing to progress discussions to secure academic

  3. Xenetic Biosciences, Inc. to Present at the April 2020 Virtual Investor Summit

    Presentation with live audio webcast on Wednesday, April 22 at 11:30 AM ET, immediately followed by an interactive Q&A sessionFRAMINGHAM, MA / ACCESSWIRE / April 15, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO)

  4. JTC Team and LaVoieHealthScience to Host Virtual Investor Summit on April 22 and 23, 2020

    Access the event and schedule of presenting companies at virtualinvestorsummit.com Live audio webcast presentations and interactive Q&A Company presentations will be held from 10 AM-12 PM ET and 1 PM-3 PM ET on

  5. Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update

    -Company continues to advance preclinical development of its XCART™ CAR T therapy platform -- Expands XCART resources by adding expertise in cell therapy translational science and CMC -- Cash on hand expected to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 enrolment closed in March 2019 due to slow enrolment.
XBIO-101
Endometrial cancer

Latest News

  1. Xenetic Biosciences, Inc. Announces Research and Development Collaboration with Scripps Research to Advance XCART(TM) Platform

    - Represents significant milestone in strategic development plan to advance XCART through academic collaborations - - Provides access to leading research institution with world renowned immunology expertise - - Company

  2. Xenetic Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update

    - Company poised to execute on near- and long-term value-driving milestones to advance preclinical development of its XCART™ CAR T therapy platform -- Continuing to progress discussions to secure academic

  3. Xenetic Biosciences, Inc. to Present at the April 2020 Virtual Investor Summit

    Presentation with live audio webcast on Wednesday, April 22 at 11:30 AM ET, immediately followed by an interactive Q&A sessionFRAMINGHAM, MA / ACCESSWIRE / April 15, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO)

  4. JTC Team and LaVoieHealthScience to Host Virtual Investor Summit on April 22 and 23, 2020

    Access the event and schedule of presenting companies at virtualinvestorsummit.com Live audio webcast presentations and interactive Q&A Company presentations will be held from 10 AM-12 PM ET and 1 PM-3 PM ET on

  5. Xenetic Biosciences, Inc. Reports 2019 Year End Results and Provides Corporate Update

    -Company continues to advance preclinical development of its XCART™ CAR T therapy platform -- Expands XCART resources by adding expertise in cell therapy translational science and CMC -- Cash on hand expected to

  6. Xenetic Biosciences' Webcast Replay from Noble Capital Markets' 16th Annual Investor Conference Presentation Now Available

    FRAMINGHAM, MA / ACCESSWIRE / February 27, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized

  7. Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board

    - Dr. MacMichael brings over 35 years of experience in development and manufacture of therapeutic proteins, vaccines, and cell and gene therapies -- Dr. MacMichael to play key role in guiding cell therapy CMC to advance

  8. Xenetic Biosciences, Inc. Strengthens Expertise to Advance XCART Development Program with Appointment of Cell Therapy Expert, Maksim Mamonkin, Ph.D. to Scientific Advisory Board

    Leading research expert in developing new therapeutic tools to treat hematologic malignancies and solid tumors using adoptive cell therapyDr. Mamonkin is a faculty member in the Center for Cell and Gene Therapy at Baylor

  9. Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference

    Presentation on Tuesday, February 18th 2020 at 2:30 p.m. ET FRAMINGHAM, MA / ACCESSWIRE / February 11, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical

  10. Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology

    - SHP656 program utilized Xenetic's PolyXen platform technology to conjugate polysialic acid to therapeutic blood-clotting factors - Phase 1/2 study demonstrated SHP656's efficacy and pharmacokinetic data

  11. Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - Company ramps up activities to execute XCART's preclinical and regulatory strategy -- Cash runway expected to fund Company through preclinical advancements towards IND filing -FRAMINGHAM, MA / ACCESSWIRE / November

  12. Xenetic Biosciences, Inc. Provides Business Outlook

    Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value for shareholders Management working with KOLs and subject matter experts to formalize XCART